Tech Company Financing Transactions
VelaVigo Funding Round
ShunWei Capital, Everest Venture Group and Hankang Capital joined a $60 million funding round for VelaVigo. The round was announced on 7/29/2025.
Transaction Overview
Company Name
Announced On
7/29/2025
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 1, 215 South Fute Rd, Pudong New Area
Shanghai, PRC, 200131
China
Shanghai, PRC, 200131
China
Phone
Website
Email Address
Overview
VelaVigo was founded by Dr. Jing Li, a renowned biopharma executive, in October 2021. We leverage discovery as an innovative engine with an emphasis on novel technologies, including bispecific/multi-specific antibodies, ADC, and new modalities. We are committed to building full capabilities covering the entire value chain of drug discovery and development, including novel discovery technology platform, translational medicine, CMC, clinical development and commercialization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Jing Li
Browse more venture capital transactions:
Prev: 7/29/2025: Seal Security venture capital transaction
Next: 7/29/2025: Arbital Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs